The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Open accessAbstract
Previously, we have shown somatostatin receptor (SSTR) subtype-specific regulation of growth hormone (GH), thyroid-stimulating hormone, and prolactin (PRL) secretion in human fetal pituitary cultures, where GH and thyroid-stimulating hormone are mediated by both SSTR2 and SSTR5, whereas SSTR2 preferentially mediates PRL secretion. We now tested SSTR subtype-selective analogues in primary human GH- and PRL-secreting pituitary adenoma cultures. Analogue affinities determined by membrane radioligand binding in cells stably expressing human SSTR forms were either SSTR2 or SSTR5-selective. Analogues preferential either for SSTR2, including octreotide, lanreotide, and novel compounds with improved affinity for SSTR2, or new SSTR5-selective compounds suppressed GH in tumor cell cultures (up to 44% of control; P < 0.0005). However, novel analogues from both groups were 30-40% more potent than octreotide and lanreotide in suppressing GH (P < 0.05). Heterologous analogue combinations containing both SSTR2- and SSTR5-selective compounds were more potent in decreasing GH than analogues used alone (P < 0.05), or than combinations of compounds specific for the same receptor subtype (P < 0.005). In contrast, SSTR2-selective analogues did not suppress PRL release from six cultured prolactinomas studied. However, new SSTR5-selective analogues suppressed in vitro PRL secretion (30-40%; P < 0.05) in four of six prolactinomas. These results suggest that both SSTR2 and SSTR5 are involved in GH regulation in somatotroph adenoma cells, whereas SSTR5 exclusively regulates PRL secretion from prolactinoma cells. Thus, somatostatin analogues with improved selective binding affinity for these receptor subtypes may be effective in the treatment of either GH- or PRL-secreting adenomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Molecular Biology of Somatostatin Receptors*
REISINE, T., & BELL, G. I. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-427 · Cited by 618
Clonal Origin of Pituitary Adenomas*
HERMAN, V., FAGIN, J., GONSKY, R., KOVACS, K., & MELMED, S. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-6-1427 · Cited by 560
Self-citationTixier‐Vidal, A., & Farquhar, M. G. (1975) · Cited by 415
Shimon, I., Taylor, J. E., Dong, J. Z., Bitonte, R. A., Kim, S., Morgan, B., Coy, D. H., Culler, M. D., & Melmed, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119225 · Cited by 309
Self-citationKubota, A., Yamada, Y., Kagimoto, S., Shimatsu, A., Imamura, M., Tsuda, K., Imura, H., Seino, S., & Seino, Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117090 · Cited by 269
Resistance to Bromocriptine in Prolactinomas
PELLEGRINI, I., RASOLONJANAHARY, R., GUNZ, G., BERTRAND, P., DELIVET, S., JEDYNAK, C. P., KORDON, C., PEILLON, F., JAQUET, P., & ENJALBERT, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-500 · Cited by 267
Newman, C. B., Melmed, S., Snyder, P. J., Young, W. F., Boyajy, L. D., Levy, R., Stewart, W. N., Klibanski, A., Molitch, M. E., & Gagel, R. F. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673422 · Cited by 245
Self-citationSomatostatin receptor subtype gene expression in pituitary adenomas
Miller, G. M. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.4.1386 · Cited by 220
Surgical Management of Acromegaly
Fahlbusch, R., Honegger, J., & Buchfelder, M. (1992) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30208-1 · Cited by 201
Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly
Melmed, S. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.12.3395 · Cited by 196
Self-citationGreenman, Y. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.3.724 · Cited by 190
Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors
Panetta, R., & Patel, Y. C. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00956-2 · Cited by 185
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors
Greenman, Y. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.2.398 · Cited by 180
Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide1
Caron, P. J., Morange, I., Cogne, M., & Jaquet, P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3714 · Cited by 179
Molecular biology of somatostatin receptors
Reisine, T. (1995) · Endocrine Reviews · doi:10.1210/er.16.4.427 · Cited by 179
Sandostatin LAR in Acromegalic Patients: Long Term Treatment
Fløgstad, A. K., Halse, J., Bakke, S. J., Lancranjan, I., Marbach, P., Bruns, C., & Jervell, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3572 · Cited by 176
Somatostatin receptors in human prostate and prostate cancer.
Reubi, J. C., Waser, B., Schaer, J., et al. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673428 · Cited by 106
Prolactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma)
Berezin, M., Shimon, I., & Hadani, M. (1995) · Journal of Endocrinological Investigation · doi:10.1007/bf03349742 · Cited by 103
Self-citationReceptor-specific somatostatin analogs: Correlations with biological activity
Coy, D. H., & Taylor, J. E. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90073-6 · Cited by 56
Self-citationIshibashi, M., & YAMAJI, T. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-5-985 · Cited by 46
Newman, C. B., Melmed, S. K., Snyder, P. J., Young, W. F., Boyajy, L. D., Levy, R., Stewart, W., Klibanski, A., Molitch, M. E., Gagel, R. F., et al. (1995) · The Journal of Clinical Endocrinology & Metabolism · Cited by 32
Self-citationIshibashi, M., & YAMAJI, T. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-3-599 · Cited by 25
Cited by
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Guidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Metadata
- Authors
- Shimon, I., Yan, X., Taylor, J. E., Weiss, M. H., Culler, M. D., & Melmed, S.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-11-01
- Volume
- 100
- Issue
- 9
- Pages
- 2386-2392
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2160694019
- Cited by
- 260
- References
- 23
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.